Galectin Therapeutics Inc.

2.60+0.4100+18.72%Vol 9.30M1Y Perf 44.96%
Apr 19th, 2021 14:59 DELAYED
BID2.60 ASK2.61
Open2.30 Previous Close2.19
Pre-Market2.26 After-Market-
 0.07 3.20%  - -
Target Price
14.00 
Analyst Rating
Strong Buy 1.00
Potential %
442.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/-/50 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-85/-46 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/-85/-50 
Income Ranking
 —    -
Market Cap148.61M 
Earnings Rating
Buy
Price Range Ratio 52W %
41.86 
Earnings Date
10th May 2021

Today's Price Range

2.232.70

52W Range

1.703.85

5 Year PE Ratio Range

-7.20-3.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-16.41%
1 Month
-6.81%
3 Months
0.00%
6 Months
-21.51%
1 Year
44.96%
3 Years
-36.71%
5 Years
31.14%
10 Years
-70.80%

TickerPriceChg.Chg.%
GALT2.600.410018.72
AAPL134.580.42000.31
GOOG2 300.292.53000.11
MSFT259.00-1.7400-0.67
XOM56.19-0.4700-0.83
WFC44.160.32000.73
JNJ162.910.67000.41
FB302.14-4.0400-1.32
GE13.410.02000.15
JPM153.17-0.1300-0.08
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.16-0.1412.50
Q03 2020-0.14-0.1028.57
Q02 2020-0.09-0.11-22.22
Q01 2020-0.08-0.0625.00
Q04 2019--0.12-
Q03 2019-0.09-0.0544.44
Q02 2019-0.12-0.0650.00
Q01 2019-0.14-0.0842.86
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.170.00-
6/2021 QR-0.160.00-
12/2021 FY-0.680.00-
12/2022 FY-0.870.00-
Next Report Date10th May 2021
Estimated EPS Next Report-0.17
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume9.30M
Shares Outstanding57.16M
Trades Count25.98K
Dollar Volume744.76K
Avg. Volume1.62M
Avg. Weekly Volume15.52M
Avg. Monthly Volume5.07M
Avg. Quarterly Volume1.86M

Galectin Therapeutics Inc. (NASDAQ: GALT) stock closed at 2.19 per share at the end of the most recent trading day (a -1.79% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 148.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 7 people. Galectin Therapeutics Inc. CEO is Joel Lewis.

The one-year performance of Galectin Therapeutics Inc. stock is 44.96%, while year-to-date (YTD) performance is -2.23%. GALT stock has a five-year performance of 31.14%. Its 52-week range is between 1.7 and 3.85, which gives GALT stock a 52-week price range ratio of 41.86%

Galectin Therapeutics Inc. currently has a PE ratio of -6.30, a price-to-book (PB) ratio of 6.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -57.31%, a ROC of -54.64% and a ROE of -68.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Galectin Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Galectin Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Galectin Therapeutics Inc. is Strong Buy (1), with a target price of $14, which is +442.64% compared to the current price. The earnings rating for Galectin Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Galectin Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Galectin Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.19, ATR14 : 0.22, CCI20 : -41.00, Chaikin Money Flow : -0.37, MACD : -0.02, Money Flow Index : 91.85, ROC : 7.88, RSI : 36.12, STOCH (14,3) : 14.29, STOCH RSI : 0.30, UO : 38.39, Williams %R : -85.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Galectin Therapeutics Inc. in the last 12-months were: Gilbert F. Amelio (Sold 60 000 shares of value $130 200 ), Kevin D. Freeman (Buy at a value of $23 048), Richard E. Uihlein (Buy at a value of $25 500)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.

CEO: Joel Lewis

Telephone: +1 678 620-3186

Address: 4960 Peachtree Industrial Boulevard, Norcross 30071, GA, US

Number of employees: 7

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

45%55%

Bearish Bullish

57%43%

News

Stocktwits